Developing 10E5-1, an anti-activin A antibody delivered via mRNA-LNP, to suppress pathogenic antibody production and treat rheumatoid arthritis through a novel mechanism.
Building the largest cerebrospinal fluid immune profile dataset in pediatric autoimmune neurological diseases to enable faster, more accurate diagnosis of MS and related conditions.
Developing CART4-34, a novel CAR T cell therapy that selectively eliminates IGHV4-34+ pathogenic B cells in lupus while sparing healthy B cells and avoiding broad immunosuppression.
Building a spatial single-cell atlas of healthy and diseased human kidneys to redefine immune-mediated kidney disease and identify precision diagnostic and therapeutic targets.
Advancing engineered CAR and CAAR T cell therapies across multiple autoimmune diseases through clinical trials, preclinical development, and industry partnerships.
